We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+3.58%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$69.4B
AUM Growth
+$3.54B
Cap. Flow
+$1.44B
Cap. Flow %
2.08%
Top 10 Hldgs %
21.44%
Holding
3,843
New
225
Increased
1,690
Reduced
1,576
Closed
217

Sector Composition

Rank Sector Weight
1 Technology 10.52%
2 Financials 9.29%
3 Healthcare 8.12%
4 Industrials 6.67%
5 Consumer Discretionary 5.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PSX icon
226
Phillips 66
PSX
$81.4B
$56.9M 0.08%
607,922
-194,273
-24% -$17.4M
BUD icon
227
AB InBev
BUD
$165B
$56.7M 0.08%
640,073
+68,530
+12% +$5.88M
VO icon
228
Vanguard Morningstar Mid-Cap ETF
VO
$109B
$56.6M 0.08%
1,353,544
+107,180
+9% +$4.39M
MMP
229
DELISTED
Magellan Midstream Partners, L.P.
MMP
$56M 0.08%
874,313
-15,963
-2% -$991K
ORI icon
230
Old Republic International
ORI
$10.4B
$55.8M 0.08%
2,494,341
-284,417
-10% -$6.26M
JNK icon
231
State Street SPDR Bloomberg High Yield Bond ETF
JNK
$6.92B
$55.7M 0.08%
511,208
+45,909
+10% +$4.95M
VOD icon
232
Vodafone
VOD
$37.4B
$55.3M 0.08%
3,388,884
-1,090,933
-24% -$18.8M
IJJ icon
233
iShares S&P Mid-Cap 400 Value ETF
IJJ
$8.97B
$55.1M 0.08%
691,388
+22,960
+3% +$1.82M
DD icon
234
DuPont de Nemours
DD
$19.2B
$54.9M 0.08%
582,848
-537,581
-48% -$64.2M
PLD icon
235
Prologis
PLD
$133B
$54.7M 0.08%
682,763
+41,096
+6% +$3.13M
CM icon
236
Canadian Imperial Bank of Commerce
CM
$108B
$54.6M 0.08%
1,392,072
-22,862
-2% -$921K
ECL icon
237
Ecolab
ECL
$79.9B
$54.4M 0.08%
275,634
-6,096
-2% -$1.13M
WTW icon
238
Willis Towers Watson
WTW
$32B
$53.8M 0.08%
280,874
-3,556
-1% -$644K
EQIX icon
239
Equinix
EQIX
$103B
$53.7M 0.08%
106,430
+13,634
+15% +$6.54M
ILMN icon
240
Illumina
ILMN
$28.4B
$53.3M 0.08%
148,721
+15,959
+12% +$5.04M
JCI icon
241
Johnson Controls International
JCI
$92.2B
$53.2M 0.08%
1,287,265
-98,796
-7% -$3.8M
CL icon
242
Colgate-Palmolive
CL
$74.4B
$53.1M 0.08%
741,207
+23,880
+3% +$1.7M
VFC icon
243
VF Corp
VFC
$5.89B
$52.9M 0.08%
606,088
+27,263
+5% +$2.35M
EEM icon
244
iShares MSCI Emerging Markets ETF
EEM
$29.5B
$52.7M 0.08%
1,227,921
-415,624
-25% -$17.6M
AZN icon
245
AstraZeneca
AZN
$250B
$52.7M 0.08%
638,070
-82,667
-11% -$6.48M
DE icon
246
Deere & Co
DE
$168B
$52.3M 0.08%
315,474
+34,475
+12% +$5.37M
FBT icon
247
First Trust NYSE Arca Biotechnology Index Fund
FBT
$2.83B
$51.9M 0.07%
368,720
+31,046
+9% +$4.28M
WY icon
248
Weyerhaeuser
WY
$18.4B
$51.8M 0.07%
1,965,285
-589,039
-23% -$15M
COP icon
249
ConocoPhillips
COP
$141B
$51.5M 0.07%
844,793
-16,097
-2% -$1M
PGR icon
250
Progressive
PGR
$125B
$51.1M 0.07%
639,354
-10,695
-2% -$827K

Similar funds

Raymond James & Associates's Q2 2019 Portfolio in Review

As of Q2 2019, Raymond James & Associates held 3,843 positions worth $69.4B, up 5.4% from $65.8B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Raymond James & Associates's Q2 2019 filing shows 225 new, 1,690 increased, 1,576 reduced and 217 closed positions. Its largest new stake was Dow Inc: 851,378 shares worth $42M. The largest sale was AbbVie, an estimated $134M.

By sector, the portfolio is most concentrated in Technology at 11% of assets, up from 11% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q2 2019 buy was Dow Inc: 851,378 shares worth $42M.
  • Raymond James & Associates added most to Medtronic in Q2 2019, an estimated $157M increase.
  • Raymond James & Associates's biggest Q2 2019 reduction was AbbVie, cutting an estimated $134M.
  • Raymond James & Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $5.43M.
  • Raymond James & Associates's ten largest holdings make up 21% of its $69.4B portfolio in Q2 2019.
  • Raymond James & Associates opened 225 new positions and closed 217 in Q2 2019.
  • Raymond James & Associates's portfolio value rose 5.4% quarter-over-quarter to $69.4B.

Based on Raymond James & Associates's 13F filing for Q2 2019, filed 6 Aug 2019.